Philip C Prorok
Overview
Explore the profile of Philip C Prorok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
4334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu P, Prorok P, Katki H
J Natl Cancer Inst
. 2024 Oct;
117(2):303-311.
PMID: 39383209
Background: Determining whether screening with multicancer detection (MCD) tests saves lives requires randomized controlled trials (RCTs). To inform RCT design, we estimated cancer-mortality outcomes from hypothetical MCD RCTs. Methods: We...
2.
Katki H, Prorok P, Castle P, Minasian L, Pinsky P
J Natl Cancer Inst
. 2024 Sep;
116(10):1675-1682.
PMID: 39267581
Background: Cancer screening trials have required large sample sizes and long time-horizons to demonstrate cancer mortality reductions, the primary goal of cancer screening. We examine assumptions and potential power gains...
3.
Katki H, Prorok P, Castle P, Minasian L, Pinsky P
J Natl Cancer Inst
. 2024 Apr;
116(8):1280-1287.
PMID: 38603624
Background: Cancer screening trials have required large sample sizes and long time-horizons to demonstrate cancer mortality reductions, the primary goal of cancer screening. We examine assumptions and potential power gains...
4.
Rubinstein W, Patriotis C, Dickherber A, Han P, Katki H, LeeVan E, et al.
CA Cancer J Clin
. 2024 Mar;
74(4):368-382.
PMID: 38517462
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early...
5.
Minasian L, Pinsky P, Katki H, Dickherber T, Han P, Harris L, et al.
J Natl Cancer Inst
. 2022 Dec;
115(3):250-257.
PMID: 36458902
Blood-based assays using various technologies and biomarkers are in commercial development for the purpose of detecting multiple cancer types concurrently at an early stage of disease. These multicancer early detection...
6.
Baker S, Prorok P
J Med Screen
. 2020 Aug;
28(2):185-192.
PMID: 32838665
Objective: According to the Independent UK Panel on Breast Cancer Screening, the most reliable estimates of overdiagnosis for breast cancer screening come from stop-screen trials Canada 1, Canada 2, and...
7.
Pinsky P, Miller E, Zhu C, Prorok P
J Med Screen
. 2019 Apr;
26(3):127-134.
PMID: 30943843
No abstract available.
8.
Miller E, Pinsky P, Schoen R, Prorok P, Church T
Lancet Gastroenterol Hepatol
. 2018 Dec;
4(2):101-110.
PMID: 30502933
Background: Screening flexible sigmoidoscopy reduces incidence and mortality of colorectal cancer. Previously reported results from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial had a median follow-up of...
9.
10.
Prorok P, Wright P, Riley T, Kramer B, Berg C, Gohagan J
Rev Recent Clin Trials
. 2018 Apr;
13(4):257-273.
PMID: 29629665
Background: Screening tests are typically evaluated for a single disease, but multiple tests for multiple diseases are performed in practice. The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial...